pharma · Systemic Sclerosis · Nonalcoholic Steatohepatitis · CMMB
Chemomab Therapeutics
Chemomab Therapeutics is a pharma organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker CMMB. Primary therapeutic focus areas include Systemic Sclerosis, Nonalcoholic Steatohepatitis, Nonalcoholic F
Tel Aviv, USA HQ
2011 Founded
20 Employees
Public company Type
CMMB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 4
- Patents
- 4
Anti-human CCL24 monoclonal antibody (CM-101)
Phase 2 · mab · Primary Sclerosing Cholangitis
Anti-human CCL24 monoclonal antibody (CM-101) for Primary Sclerosing Cholangitis is a Phase 2 program (mab) at Chemomab Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CM-101-PSC-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chemomab Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- Primary Sclerosing Cholangitis
- Status
- active
- Trials
- 1